

Quoin Pharmaceuticals Ltd.
Azrieli Center, Round Tower, 30th Floor
132 Menachem Begin Blvd
Tel Aviv, 6701101

August 4, 2022

VIA EDGAR

United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Attn: Christine Westbrook

RE: Quoin Pharmaceuticals Ltd.
Registration Statement on Form F-1
Registration No. 333-266476

Ladies and Gentlemen:

Quoin Pharmaceuticals Ltd. (the "Company") hereby requests, pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended, acceleration of the effective date of the above-referenced Registration Statement, as amended, so that such Registration Statement, as amended, will become effective at 9:00 a.m., Eastern Time, on Friday, August 5, 2022, or as soon thereafter as practicable.

[Signature Page Follows]

Very truly yours,

QUOIN PHARMACEUTICALS LTD.

By: /s/ Dr. Michael Myers

Name: Dr. Michael Myers

Title: Chief Executive Officer
